文献速递外周动脉疾病

AMPREDICT决策支持工具的开发与可用性:混合方法研究

The Development and Usability of the AMPREDICT Decision Support Tool: A Mixed Methods Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2021-06-02

该研究将先前验证的AMPREDICT预测模型转化为基于网络的临床决策支持工具,计算慢性肢体威胁性缺血患者按截肢平面个体化的一年术后死亡、再截肢风险和独立活动概率。采用混合方法,由多学科10名临床医生使用PSSUQ评估可用性,总体均分1.57(SD 0.69),范围1.00-3.21,显示良好可用性,定性访谈归纳出咨询、设定预期和教学等临床用途。

要点

  • AMPREDICT决策支持工具可计算个体化一年术后死亡、再截肢和独立活动概率。
  • 10名多学科临床医生PSSUQ总体均分1.57(SD 0.69),提示可用性良好。
  • 工具潜在用途包括辅助患者咨询、设定结果预期和学术教学。

核心结论

  • 经过迭代开发和测试,AMPREDICT决策支持工具表现出良好的可用性和临床相关性。
  • 未来需将其整合到电子健康记录中并评估对医患共享截肢平面决策的影响。

研究设计与样本

  • 混合方法研究,将先前验证的预测模型转化为基于网络的决策支持工具,并由专家小组开发额外内容和格式。
  • 由来自不同专科、性别、地域和临床经验的10名临床最终用户使用PSSUQ(16条目,1-7分,分数越低可用性越好)评估工具可用性。
  • 采用出声思维、半结构化定性访谈评估工具的外观感受、用户友好性、可读性、功能和潜在实施挑战。

主要发现

  • PSSUQ总体和子量表得分良好,总体平均总分为1.57(标准差0.69),范围1.00至3.21。
  • 工具的潜在临床效用包括:协助就截肢平面决策咨询患者、设定结果预期、作为学术环境中的工具促进理解导致各种结果风险的因素。

临床怎么用

  • 可用于辅助慢性肢体威胁性缺血患者截肢平面决策时的患者咨询。
  • 可用于设定患者对术后死亡、再截肢和独立活动等结果的预期。
  • 可作为学术环境中理解截肢结果风险因素的教学工具。

局限性

  • 可用性评估仅纳入10名临床医生,样本量有限。
  • 尚未整合到电子健康记录中,其对医患共享决策的实际影响未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Amputation level decision making in patients with chronic limb threatening ischaemia is challenging. Currently, evidence relies on published average population risks rather than individual patient risks. The result is significant variation in the distribution of amputation levels across health systems, geographical regions, and time. Clinical decision support has been shown to enhance decision making, especially complex decision making. The goal of this study was to translate the previously validated AMPREDICT prediction models by developing and testing the usability of the AMPREDICT Decision Support Tool (DST), a novel, web based, clinical DST that calculates individual one year post-operative risk of death, re-amputation, and probability of achieving independent mobility by amputation level. METHODS: A mixed methods approach was used. Previously validated prediction models were translated into a web based DST with additional content and format developed by an expert panel. Tool usability was assessed using the Post-Study System Usability Questionnaire (PSSUQ; a 16 item scale with scores ranging from 1 to 7, where lower scores indicate greater usability) by 10 clinician end users from diverse specialties, sex, geography, and clinical experience. Think aloud, semi-structured, qualitative interviews evaluated the AMPREDICT DST's look and feel, user friendliness, readability, functionality, and potential implementation challenges. RESULTS: The PSSUQ overall and subscale scores were favourable, with a mean overall total score of 1.57 (standard deviation [SD] 0.69) and a range from 1.00 to 3.21. The potential clinical utility of the DST included (1) assistance in counselling patients on amputation level decisions, (2) setting outcome expectations, and (3) use as a tool in the academic environment to facilitate understanding of factors that contribute to various outcome risks. CONCLUSION: After extensive iterative development and testing, the AMPREDICT DST was found to demonstrate strong usability characteristics and clinical relevance. Further evaluation will benefit from integration into an electronic health record with assessment of its impact on physician and patient shared amputation level decision making.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Norvell DC, Suckow BD, Webster JB, et al. The Development and Usability of the AMPREDICT Decision Support Tool: A Mixed Methods Study. Eur J Vasc Endovasc Surg. 2021. PMID: 34088615. doi:10.1016/j.ejvs.2021.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。